Ab­b­Vie jumps on the on­colyt­ics band­wag­on, em­brac­ing Turn­stone in new col­lab­o­ra­tion

Ab­b­Vie has paid for a front row seat on the can­cer drug strat­e­gy be­ing in­ves­ti­gat­ed in the clin­ic at Turn­stone Bi­o­log­ics. The phar­ma out­fit snagged an op­tion to buy Turn­stone’s lead ther­a­py com­bin­ing an on­colyt­ic virus ap­proach and can­cer vac­cine. And if they dive in, Ab­b­Vie ex­pects to line up a shot at a se­ries of tu­mor types with an op­tion on two more pro­grams that Turn­stone will work on.

“This is the largest part­ner­ship ever formed in this field,” says Turn­stone CEO Sam­my Farah, who’s clear­ly pumped to be align­ing his biotech with a promi­nent play­er in can­cer R&D. “It’s a very sig­nif­i­cant, very mean­ing­ful part­ner­ship on many lev­els.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER